Notably, the observation that the ABT-199/CS055 combination was highly active in a PDX mouse model of AML carrying FLT3-ITD highlights the promising activity of this regimen for the treatment of high-risk AML patients with poor prognosis. Here, FLT3 is linked to acute myeloid leukemia.